Original Paper

Clinical Research in Cardiology

, Volume 100, Issue 8, pp 691-699

First online:

Influence of abciximab on evolution of left ventricular function in patients with non-ST-segment elevation acute coronary syndromes undergoing PCI after clopidogrel pretreatment: lessons from the ISAR-REACT 2 trial

  • Stefanie SchulzAffiliated withDeutsches Herzzentrum, Technische Universität Email author 
  • , Julinda MehilliAffiliated withDeutsches Herzzentrum, Technische Universität
  • , Gjin NdrepepaAffiliated withDeutsches Herzzentrum, Technische Universität
  • , Franz DotzerAffiliated withKlinikum Garmisch-Partenkirchen, Zentrum für Innere Medizin/Kardiologie
  • , Michael DommaschAffiliated withDeutsches Herzzentrum, Technische Universität
  • , Sebastian KufnerAffiliated withDeutsches Herzzentrum, Technische Universität
  • , Kathrin A. BirkmeierAffiliated withDeutsches Herzzentrum, Technische Universität
  • , Klaus TirochAffiliated withDeutsches Herzzentrum, Technische Universität
  • , Robert A. ByrneAffiliated withDeutsches Herzzentrum, Technische Universität
    • , Albert SchömigAffiliated withDeutsches Herzzentrum, Technische Universität1. Medizinische Klinik, Klinikum rechts der Isar, Technische Universität
    • , Adnan KastratiAffiliated withDeutsches Herzzentrum, Technische Universität

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access



Abciximab reduced the combined endpoint of death, myocardial infarction (MI) and target vessel revascularization in patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS) undergoing percutaneous coronary intervention (PCI) with stent implantation after a 600-mg loading dose of clopidogrel. The aim of the present study was to investigate the impact of abciximab on the evolution of left ventricular ejection fraction (LVEF) in these patients.


The current study included 1,158 patients enrolled in the randomized, double-blind ISAR-REACT 2 (the Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment) trial who had paired angiograms obtained at baseline and 6–8 months after randomization. Of them, 586 patients received abciximab and 572 patients received placebo. The primary outcome analysis was LVEF at 6–8-month follow-up.


Baseline LVEF was comparable in patients assigned to abciximab or placebo (53.2 ± 12.6 vs. 53.7 ± 12.1%; P = 0.393). At 6–8-month follow-up angiography, there was no difference in LVEF between the abciximab and placebo groups (55.4 ± 11.5 vs. 55.8 ± 11.2%; P = 0.743). Subgroup analysis of patients with elevated baseline troponin (>0.03 μg/L) also revealed comparable LVEF at follow-up in both treatment groups (P = 0.527). The multivariate analysis identified age, arterial hypertension, prior MI, prior coronary artery bypass graft surgery, baseline LVEF, MI at 30 days and repeat PCI as independent correlates of follow-up LVEF.


Although abciximab reduced the 30-day and 1-year incidence of major adverse cardiac events in patients with NSTE-ACS undergoing primary PCI after pre-treatment with a 600-mg loading dose of clopidogrel, the agent did not improve or impact on the evolution of LVEF over 6–8 months of follow-up.


Abciximab Heparin Clopidogrel Stent LV function